Eli Lilly and Company (NYSE:LLY) Shares Down 2.2% - Here's What Happened

Key Points

• Business catalysts: Medicare's expansion meaningfully broadens access to Lilly’s tirzepatide drugs (Zepbound, Mounjaro) and the company announced a roughly $3 billion China manufacturing buildout, both boosting addressable market and reducing supply risk.
• Safety and regulatory risks: Lilly warned of an unknown impurity in compounded tirzepatide mixed with vitamin B12 and faces advertising/marketing limits in some countries (e.g., India), which could pressure prescribing and cause short‑term volatility.
• Financials and sentiment: Lilly beat quarterly revenue and EPS with strong year‑over‑year growth and set FY2026 guidance of 33.5–35.0 EPS; analysts are mostly bullish (average price target ~$1,230) but the stock remains richly valued (P/E ~42.6), inviting profit‑taking risk.

Eli Lilly and Company (NYSE:LLY - Get Free Report)'s share price fell 2.2% during mid-day trading on Thursday . The stock traded as low as $973.16 and last traded at $977.4720. 2,326,214 shares changed hands during trading, a decline of 28% from the average session volume of 3,211,158 shares. The stock had previously closed at $999.84.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CMS/Medicare expansion meaningfully broadens access to Lilly’s leading tirzepatide products (Zepbound, Mounjaro), increasing the company’s addressable market and supporting revenue upside. Eli Lilly (LLY) and CMS Expand Medicare Access to Zepbound and Mounjaro
• Positive Sentiment: Large, long-term China investment: Lilly announced a multi‑billion-dollar (reported ~$3B) manufacturing/supply‑chain buildout in China to secure capacity for its next‑gen oral and injectable GLP‑1s — this reduces supply risk and targets a huge, growing market. Eli Lilly to invest $3 billion in China over next decade
• Positive Sentiment: Pipeline and product catalysts remain bullish: Lilly has filed/advanced its oral GLP‑1 (orforglipron) and reported favorable head‑to‑head data vs. competitors, supporting near‑term launches and long‑term growth. This underpins analyst upside and premium valuation. Eli Lilly Widens Access to Weight-Loss Injectable as Lower-Cost Pill Nears Approval
• Positive Sentiment: Strategic ecosystem investments (Korea Gateway Labs / $500M pledge, Samsung Biologics partnership) expand R&D/partner capacity and local market presence, which can accelerate future product commercialization. Eli Lilly Taps Samsung Biologics To Grow Korean Biotech And Long Term Value
• Neutral Sentiment: Market-structure/speculation items (stock-split chatter and “GLP‑1 pill wars” coverage) keep retail interest high but are more sentiment/flow-driven than fundamental catalysts. These can amplify moves but don’t change the fundamentals immediately.
• Negative Sentiment: Lilly issued a public warning about an unknown impurity found in compounded tirzepatide mixed with vitamin B12 — safety concerns and negative headlines can pressure prescribing, invite regulatory scrutiny of compounding practices, and spur short‑term volatility. Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12
• Negative Sentiment: Sentiment/technical concerns: some analysts/commentators note fading trading momentum and “peak euphoria” for GLP‑1 names after a huge run, which can trigger profit‑taking in a richly valued stock. Eli Lilly Reaching For Peak GLP-1 Euphoria: Rotten Trading Momentum Since November
• Negative Sentiment: Regulatory/market constraints in key geographies — e.g., India warning against weight‑loss drug advertising — could limit marketing channels and slow uptake in large markets. India warns drugmakers against direct or surrogate weight-loss drug obesity ads

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Zacks Research cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Friday, January 30th. TD Cowen upped their target price on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a "buy" rating in a research report on Thursday, January 29th. Barclays started coverage on Eli Lilly and Company in a research note on Thursday, February 19th. They issued an "overweight" rating and a $1,350.00 target price on the stock. BMO Capital Markets reaffirmed an "outperform" rating and set a $1,300.00 price target on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Finally, Guggenheim upped their price objective on Eli Lilly and Company from $1,161.00 to $1,168.00 and gave the stock a "buy" rating in a report on Thursday, February 26th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $1,229.59.

Eli Lilly and Company Stock Performance

The company has a market cap of $923.54 billion, a P/E ratio of 42.59, a price-to-earnings-growth ratio of 1.16 and a beta of 0.40. The company's fifty day moving average is $1,041.12 and its 200 day moving average is $947.08. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. During the same period in the previous year, the firm posted $5.32 earnings per share. The firm's revenue for the quarter was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Eli Lilly and Company

Several institutional investors have recently bought and sold shares of LLY. Farmers National Bank boosted its stake in shares of Eli Lilly and Company by 8.4% during the fourth quarter. Farmers National Bank now owns 4,456 shares of the company's stock valued at $4,789,000 after purchasing an additional 345 shares during the period. Winthrop Partners WNY LLC purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth $644,000. Nalls Sherbakoff Group LLC bought a new stake in Eli Lilly and Company during the 4th quarter valued at $46,000. Meadowbrook Advisors Group LLC bought a new stake in Eli Lilly and Company during the 4th quarter valued at $764,000. Finally, Green Ridge Wealth Planning LLC purchased a new stake in Eli Lilly and Company during the 4th quarter valued at $925,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.